- Home
- BLKB vs DNLI Comparison
BLKB vs DNLI Comparison
Compare BLKB & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLKB
- DNLI
- Stock Information
- Founded
- BLKB 1981
- DNLI 2013
- Country
- BLKB United States
- DNLI United States
- Employees
- BLKB N/A
- DNLI N/A
- Industry
- BLKB Computer Software: Prepackaged Software
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLKB Technology
- DNLI Health Care
- Exchange
- BLKB Nasdaq
- DNLI Nasdaq
- Market Cap
- BLKB 3.9B
- DNLI 3.3B
- IPO Year
- BLKB 2004
- DNLI 2017
- Fundamental
- Price
- BLKB $79.72
- DNLI $23.69
- Analyst Decision
- BLKB Hold
- DNLI Strong Buy
- Analyst Count
- BLKB 3
- DNLI 13
- Target Price
- BLKB $86.67
- DNLI $38.00
- AVG Volume (30 Days)
- BLKB 156.4K
- DNLI 1.1M
- Earning Date
- BLKB 02-14-2025
- DNLI 02-25-2025
- Dividend Yield
- BLKB N/A
- DNLI N/A
- EPS Growth
- BLKB N/A
- DNLI N/A
- EPS
- BLKB 0.99
- DNLI N/A
- Revenue
- BLKB $1,148,274,000.00
- DNLI N/A
- Revenue This Year
- BLKB $6.75
- DNLI N/A
- Revenue Next Year
- BLKB $4.32
- DNLI $651.24
- P/E Ratio
- BLKB $79.62
- DNLI N/A
- Revenue Growth
- BLKB 5.81
- DNLI 204.74
- 52 Week Low
- BLKB $66.47
- DNLI $14.56
- 52 Week High
- BLKB $88.95
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- BLKB 61.21
- DNLI 53.06
- Support Level
- BLKB $75.09
- DNLI $21.55
- Resistance Level
- BLKB $78.32
- DNLI $24.29
- Average True Range (ATR)
- BLKB 1.42
- DNLI 1.22
- MACD
- BLKB 0.40
- DNLI 0.17
- Stochastic Oscillator
- BLKB 100.00
- DNLI 73.14
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.